Close

Ocular Therapeutix (OCUL) Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial Mar 3, 2020 07:36AM
Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Con Mar 3, 2020 07:30AM
Ocular Therapeutix (OCUL) Presents Data Demonstrating Reduction in IOP in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC Feb 7, 2020 08:03AM
Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Feb 7, 2020 08:00AM
Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update Nov 12, 2019 07:00AM


Nov 8, 2019 04:02PM Ocular Therapeutix (OCUL) Announces Strategic Update and Operational Restructuring
Nov 8, 2019 04:01PM Ocular Therapeutix Announces Strategic Update and Operational Restructuring
Aug 1, 2017 04:09PM Ocular Therapeutix (OCUL) Says Antony Mattessich Assumes Role as CEO; Amar Sawhney has Transitioned to Executive Chairman
Aug 1, 2017 04:05PM Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer